LPLevon B. Piotrovskiy

Levon B. Piotrovskiy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Levon B. Piotrovskiy has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outstanding chemist Nikolai V. Khromov-Borisov: on the 120th anniversary of birth

    by Elena V. Litasova, Levon B. Piotrovskiy

    This year marks the 120th anniversary of the birth of the outstanding Soviet scientist, Doctor of Chemical Sciences, Professor, and Corresponding Member of the Academy of Medical Sciences of the USSR, Nikolai V. Khromov-Borisov. The principal focus of N.V. Khromov-Borisov’s scientific work was the investigation of the structure of the cholinergic receptor using pharmacochemical approaches. His studies of the relationship between spatial molecular structure and curare-like activity, as well as the influence of the distance between cationic groups on molecular activity, enabled him, together with M.Ya. Michelson, to formulate the hypothesis of the tetrameric structure of the cholinergic receptor. It should be emphasized that this work was carried out in the mid-1960s, when molecular biological methods were not yet sufficiently developed to isolate and study receptor proteins and complexes. In subsequent years, new research techniques refined the understanding of cholinergic receptor structure and established the precise site of action of bis-cationic compounds. Nevertheless, the tetrameric model proposed by N.V. Khromov-Borisov and M.Ya. Michelson significantly facilitated the rational design of muscle relaxants and contributed to the development of both short-acting and long-acting agents. His application of quantum chemistry and molecular mechanics to conformational studies of biologically active molecules and to the determination of three-dimensional pharmacophore structures allows N.V. Khromov-Borisov to be regarded as an outstanding chemist. His work laid the foundation for molecular drug design. A brilliant chemist involved in the development of numerous medicinal products, an excellent educator whom students regarded as one of the finest lecturers of the First Leningrad Medical Institute, and a broadly educated and creatively gifted individual—all of these descriptions aptly characterize Nikolai V. Khromov-Borisov.

  • Absorption, distribution, metabolism and excretion of carbon nanostructures

    by Elena V. Litasova, Viktor V. Iljin, Levon B. Piotrovskiy

    The interaction of any substance with the body is determined by several parameters, namely: its adsorption, distribution, metabolism, and excretion (ADME properties). Naturally, this also fully applies to such a class of compounds as carbon nanostructures. They are mostly composed of sp2-hybridized carbon atoms (except for nanodiamonds, which consist of sp3-hybridized atoms). However, they differ significantly in their properties. This review focuses on these differences. It covers fullerenes, nano-onions, carbon nanotubes, carbon nanohorns, graphene and its derivatives, as well as nanodiamonds.


  • Противосудорожная активность 6,7-дигидро-5H-пирроло[1,2-a]имидазол-2,3-дикарбоновой кислоты и ее бис-метиламида

    by Мария Александровна Брусина, Александр Михайлович Потапкин, Лариса Георгиевна Кубарская, Елена Викторовна Литасова, Левон Борисович Пиотровский

    Исследован противосудорожный потенциал нового лиганда NMDA-рецептора — 6,7-дигидро-5H-пирроло[1,2-a]имидазол-2,3-дикарбоновой кислоты и одного из ее возможных пролекарств — бис-метиламида на моделях NMDA- и коразол-индуцированных судорог у мышей. Влияние этих соединений на ионные токи, вызванные аппликацией NMDA, исследовано на изолированных нейронах среднего мозга зебраданио методом patch-clamp. На изолированных нейронах показано, что 6,7-дигидро-5H-пирроло[1,2-a]имидазол-2,3-дикарбоновая кислота оказывает блокирующее действие на NMDA-рецептор. Обнаружено, что 6,7-дигидро-5H-пирроло[1,2-a]имидазол-2,3-дикарбоновая кислота и ее бис-метиламид проявляют выраженную противосудорожную активность в отношении NMDA-индуцированных судорог и не активны на модели коразоловых судорог у мышей. Эффективная доза бис-метиламида на модели NMDA-индуцированных судорог в 4,5 раза ниже дозы кислоты.


  • Open Access

    Analgesic activity of new ligands of the NMDA receptor complex

    by Ekaterina E. Yakovleva, Mekhriniso T. Kamalova, Mariia A. Brusina, Evgenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov, Камалова Мехринисо

    BACKGROUND: The activation of spinal cord NMDA receptors is a key factor in the pathogenesis of acute and chronic pain. Therefore, the use of existing NMDA antagonists in analgesic schemes and the development of new compounds targeting the NMDA receptor complex are gaining attention. New ligands of the glutamate NMDA receptor complex are derivatives of imidazole-4,5-dicarboxylic acid. The conformational rigidity of the molecules of imidazole-4,5-dicarboxylic acid derivatives allows for increased selectivity of interaction and reduced side effects. AIM: This study aimed to investigate the analgesic effect of new ligands of the glutamate NMDA receptor complex, which are derivatives of imidazole-4,5-dicarboxylic acid, in rats using the tail-flick test and the formalin test. MATERIALS AND METHODS: The analgesic activity of the compounds was examined in a model of acute somatic (thermal) pain in the tail-flick test and model of somatic pain induced by algogens in the formalin test. The tested compounds (IEM-303 and IEM-2044) were administered intraperitoneally at doses of 5, 10, 15, and 20 mg/kg. Мetamizole was used as the comparison drug. RESULTS: The experiments demonstrated a significant dose-dependent analgesic effect of the tested compounds on the experimental models of acute pain at doses of 5–20 mg/kg. The tail-flick latency increased by 1.4–1.7 times in the IEM-2044 and IEM-303 groups compared with the value in the control group. CONCLUSIONS: The analgesic activity of the tested compounds at 10–20 mg/kg doses was comparable to that of metamizole, indicating the prospect of developing these agents and further searching for effective and safe analgesics in this pharmacological class.

  • Open Access

    Antidyskinetic activity of new derivatives of inydazol-4,5-dicarbonic acid in a parkinsonism experimental model due to administration of 6-hydroxydopapine

    by Vladimir D. Dergachev, Ekaterina E. Yakovleva, Maria A. Brusina, Evgenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov

    BACKGROUND: Levodopa therapy currently remains the clinical method of choice for patients with Parkinsons disease. However, in the late stages of the disease, approximately 80% of patients receiving treatment developed levodopa-induced dyskinesia. The studied substances are derivatives of imidazole-4,5-dicarboxylic acid. Their pharmacological effect is produced due to interaction with the recognition site of NMDA receptor, which, together with their high efficiency, implies that they are safer than previously available drugs in this pharmacological group. AIM: To study the antidyskinetic effect of IEM2295 and IEM2296 derivatives of imidazole-4,5-dicarboxylic acid. MATERIALS AND METHODS: The model is based on the toxic effect of 6-hydroxydopamine on rat brain tissue. The first (control) group of rats received injections of only Levodopa and Benserazide, the second group received injections of Levodopa, Benserazide, and the test substance IEM2295, and the third group received injections of Levodopa, Benserazide and the test substance IEM2296. Each group was evaluated based on three criteria: motor function violations, limb dyskinesia, and axial and chewing dyskinesia. The severity of motor functions was graded on a scale of 0 to 4 points at 35, 70, 105, and 140 minutes after injection of the above substances, where 0 and 4 represent the absence and most pronounced degree of pathological movements, respectively. RESULTS: The result analysis showed that the greatest effect on reducing the severity of limb dyskinesia, axial dyskinesia, and chewing dyskinesia in rats was observed at 105 and 140 minutes after injections of the studied substances. Statistically significant differences between the control group and rats receiving injections of the studied substances were revealed at all the time points for limb dyskinesia; i.e., at 35, 105, and 140 minutes for axial dyskinesia and at 105 and 140 minutes for chewing dyskinesia. CONCLUSIONS: In the experimental model of parkinsonism, IEM2295 and IEM2296 show antiparkinsonian and antidyskinetic activity because they reduce the severity of motor function disorders in rats with levodopa-induced dyskinesia. The results indicate the prospects for continued development of these substances and further research for effective and safe antiparkinsonian agents among compounds of this class.

  • Open Access

    Toxicology of carbon nanostructures. Part 2. Nanoscale materials based on graphene sheets

    by Elena V. Litasova, Victor V. Iljin, Maria A. Brusina, Levon B. Piotrovskiy, Ильин Виктор Владимирович

    The review is a continuation of the previously published one on the toxicity of spherical nanostructures of carbon, namely fullerenes and nanoonions. This review considers data on the toxicity of carbon nanostructures in sp2-hybridization of carbon atoms, which can be considered as formed from graphene sheets, and nanostructures formed by carbon atoms in sp3-hybridization, namely, nanodiamonds. Unfortunately, it should be repeated the conclusion made in the previous review that at the moment there is not enough data to use carbon nanostructures in practice, and therefore it is necessary to develop more effective and informative tests on animals, taking into account the characteristics of each type of nanomaterials.


  • Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy

    by Vladimir D. Dergachev, Ekaterina E. Yakovleva, Maria A. Brusina, Evgeny R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov

    Introduction: To study the antiparkinsonian activity of new ligands of the glutamate NMDA receptor complex – 1,2–substituted imidazole-4,5-dicarboxylic acids – on an experimental model of catalepsy caused by haloperidolintraabdominal injections in rats. Materials and methods: The experiments were performed on Wistar rats weighing 300-350 g, obtained from the Rappolovo nursery of the Russian Academy of Medical Sciences (Leningrad Region). The animals were kept in standard plastic cages in vivarium conditions with free access to water and food at a temperature of 22±2 °C and in the experiment were divided into several groups (6 animals each). All the experiments were carried out in the autumn-winter period. The animals were kept in accordance with the rules of laboratory practice (GLP), regulatory documents ”Sanitary Rules for the Device, Equipment and Maintenance of Vivarium” and the Order of the Ministry of Health and Social Development of the Russian Federation dated 23.08.2010 No. 708n “On Approval of the Rules of Laboratory Practice”. Imidazole-dicarboxylic acid derivatives (IEM-2295, IEM-2296) were injected intraperitoneally at doses from 5 mg/kg to 40 mg/kg simultaneously with haloperidol at a dose of 1 mg/kg, after which the duration and severity of catalepsy were evaluated after 30, 60, 120 minutes from 0 to 6 points according to the Morpurgo method. Results: The severity of catalepsy with the injection of IEM-2295 decreased on average to 3 points, while in the control group it remained at the level of 6 points throughout the observation. However, the severity of catalepsy with the introduction of IEM-2296 decreased to an average of 4 points, but the effect itself lasted longer than with the introduction of IEM-2295. Thus, it was noted that by the 120th minute of observation, the severity of catalepsy in rats receiving the IEM-2295 compound averaged 5 points, whereas in animals receiving IEM-2296 – 3 points. Discussion: Basing on the results of our work and similar experiments, we can conclude that the studied compounds, which are not channel blockers, have an active effect on dopaminergic neurotransmission, because of which the symptoms of catalepsy that occur when haloperidol is injected to rats were stopped to one degree or another. Conclusion: The studied substances exhibit antiparkinsonian activity on an experimental haloperidol model of catalepsy in rats and are promising for development as potential therapies for neurodegenerative diseases. Further study of these compounds and other ligands from the NMDA-blocker group in a wider sample on the catalepsy model, as well as on other models of Parkinsonism, is required. Graphical Abstract


  • Open Access

    Toxicology of carbon nanostructures. Part 2. Nanoscale materials based on graphene sheets

    by Elena V. Litasova, Victor V. Iljin, Maria A. Brusina, Levon B. Piotrovskiy, Ильин Виктор Владимирович

    The review is a continuation of the previously published one on the toxicity of spherical nanostructures of carbon, namely fullerenes and nanoonions. This review considers data on the toxicity of carbon nanostructures in sp2-hybridization of carbon atoms, which can be considered as formed from graphene sheets, and nanostructures formed by carbon atoms in sp3-hybridization, namely, nanodiamonds. Unfortunately, it should be repeated the conclusion made in the previous review that at the moment there is not enough data to use carbon nanostructures in practice, and therefore it is necessary to develop more effective and informative tests on animals, taking into account the characteristics of each type of nanomaterials.

  • Open Access

    NMDA-рецепторы как фармакологическая мишень

    by Левон Борисович Пиотровский, Л. Г. Кубарская, М. А. Брусина

    Обсуждаются роль и возможности различных сайтов NMDA-рецепторов (глицин-связывающего сайта, блокаторов ионного канала и других) в дизайне новых нейротропных лекарственных средств, избирательно действующих на эти рецепторы. Обсуждаются пути создания нового класса препаратов, мишенью действия которых является глутамат-«узнающий» сайт NMDA-рецепторов, определяющий специфичность последних. Выделены основные этапы дизайна подобных препаратов, включая и стадию создания пролекарств.

  • Open Access

    Coumarins as a base for the drug development: yes or no?

    by Elena V. Litasova, Viktor V. Iljin, Leonid V. Myznikov, Maria A. Brusina, Levon B. Piotrovskiy

    It is well known that coumarin derivatives are widely distributed in nature and have a wide spectrum of biological activity. At the same time, only a few compounds containing a coumarin fragment are used in the clinics. These compounds include for example the anticoagulant warfarin and the anthelmintic drug haloxon. In the present article is discussed the few examples of biological activity of coumarin derivatives, the mechanisms of action of these compounds and the problems that arise in the development of new drugs, as well as the prospects for using coumarins as leader compounds.